Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Reports of supply problems with lactating cow intramammary antibiotics
The VMD has been made aware of supply problems with seven lactating cow intramammary antibiotics.

VMD informed of availability issues

The Veterinary Medicines Directorate (VMD) has been informed by Marketing Authorisation Holders (MAHs) of supply problems with certain lactating cow intramammary antibiotics.

The following is a list of lactating cow intramammary antibiotics that the VMD has noted availability problems with, along with anticipated resolution dates for each product:

Product Anticipated resolution date (subject to change)
Synulox Lactating Cow Intramammary Suspension (42058/4143) To be confirmed
Tetra-Delta Intramammary Suspension (42058/4152) February/March 2020
Ubro Yellow Milking Cow Intramammary Suspension (08327/4305) Product discontinued – no return date
Multiject IMM Intramammary Suspension (02000/4062) May 2020
Albiotic 330mg/100mg Intramammary Solution (30282/4035) End of February 2020*
Mastiplan LC. 300mg/20mg Intramammary Suspension (01708/4534) End of June 2020
Cobactan MC Intramammary Suspension for Lactating Cows (42810/4000) End of June 2020

These lactating cow intramammary products have been reported as available for veterinary surgeons to purchase:

  • Ubrolexin Intramammary Suspension for Lactating dairy cows (08327/4306)
  • Procapen Injector 3g intramammary suspension for cattle (24745/4023)
  • Orbenin L.A. 200mg Intramammary Suspension (42058/4090)
  • Pathocef 250mg Intramammary Suspension (42058/4094)

For further details on the supply situation for individual UK-authorised products, please contact the MAH or a wholesale dealer.

The VMD states that it supports and encourages responsible use of antibiotics. This however, requires veterinary surgeons to take into account, not only the most appropriate active substances, but also the most appropriate formulation, the posology, the current pattern of resistance in their locality, an awareness of how to reduce selection pressure and added requirements such as good biosecurity and husbandry.

If a veterinary surgeon can demonstrate that these steps have been taken, then VMD says cascade use of antibiotics may be considered.

Veterinary surgeons who wish to use an alternative product authorised outside of the UK to cover their immediate needs may submit an import certificate application to the VMD.

More information can be found on GOV.UK.

*In its latest update, the VMD revised its anticipated resolution date for Albiotic to the end of March 2020. 

 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.